A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer
暂无分享,去创建一个
Runsen Jin | Hecheng Li | Yichao Han | S. Liu | Yi‐Long Wu | Wang Meng
[1] L. Paz-Ares,et al. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC , 2023, Nature Reviews Clinical Oncology.
[2] Caicun Zhou,et al. Non‐small cell lung cancer in China , 2022, Cancer communications.
[3] I. Wistuba,et al. Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee. , 2022, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[4] Binzhi Qian,et al. Macrophage diversity in cancer revisited in the era of single-cell omics. , 2022, Trends in immunology.
[5] B. Nakken,et al. Tetraspanin CD53 controls T cell immunity through regulation of CD45RO stability, mobility, and function. , 2022, Cell reports.
[6] B. Győrffy,et al. Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review , 2022, Journal of Translational Medicine.
[7] G. Zhu,et al. The CD8α–PILRα interaction maintains CD8+ T cell quiescence , 2022, Science.
[8] Joe Y. Chang,et al. Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. , 2022, Journal of the National Comprehensive Cancer Network : JNCCN.
[9] A. Saliba,et al. Type 1 conventional dendritic cells maintain and guide the differentiation of precursors of exhausted T cells in distinct cellular niches. , 2022, Immunity.
[10] Shugeng Gao,et al. Worldwide burden and epidemiological trends of tracheal, bronchus, and lung cancer: A population-based study , 2022, EBioMedicine.
[11] C. Sautès-Fridman,et al. C1q+ macrophages: passengers or drivers of cancer progression. , 2022, Trends in cancer.
[12] B. Nabet,et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. , 2022, Cancer cell.
[13] P. Laurent-Puig,et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. , 2022, Immunity.
[14] M. Hellmann,et al. First-Line Immunotherapy for Non-Small-Cell Lung Cancer. , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Xueda Hu,et al. Temporal single-cell tracing reveals clonal revival and expansion of precursor exhausted T cells during anti-PD-1 therapy in lung cancer , 2021, Nature Cancer.
[16] Xueda Hu,et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells , 2021, Science.
[17] S. Keith,et al. Association Between Sex and Immune Checkpoint Inhibitor Outcomes for Patients With Melanoma , 2021, JAMA network open.
[18] Yi-long Wu,et al. Prediction of unfavourable response to checkpoint blockade in lung cancer patients through an integrated tumour-immune expression score , 2021, Translational oncology.
[19] G. Giaccone,et al. Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta-analysis of randomized clinical trials , 2021, ESMO open.
[20] V. Swarup,et al. Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer’s disease , 2021, Nature Genetics.
[21] Xiaochen Bo,et al. clusterProfiler 4.0: A universal enrichment tool for interpreting omics data , 2021, Innovation.
[22] J Zhang,et al. Single-cell profiling of tumor heterogeneity and the microenvironment in advanced non-small cell lung cancer , 2021, Nature Communications.
[23] I. Wistuba,et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors , 2021, Nature Reviews Clinical Oncology.
[24] A. Jemal,et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.
[25] Xueda Hu,et al. A pan-cancer single-cell transcriptional atlas of tumor infiltrating myeloid cells , 2021, Cell.
[26] P. Van Loo,et al. Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition , 2021, Cell.
[27] A. Goodman,et al. The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. , 2020, Cancer cell.
[28] Raphael Gottardo,et al. Integrated analysis of multimodal single-cell data , 2020, Cell.
[29] T. Owonikoko,et al. Efficacy and safety of immune checkpoint blockade in self‐identified Black patients with advanced non–small cell lung cancer , 2020, Cancer.
[30] Young-Joon Kim,et al. Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer , 2020, Experimental & Molecular Medicine.
[31] Xiaole Shirley Liu,et al. TIMER2.0 for analysis of tumor-infiltrating immune cells , 2020, Nucleic Acids Res..
[32] J. Valcárcel,et al. Roles and mechanisms of alternative splicing in cancer — implications for care , 2020, Nature Reviews Clinical Oncology.
[33] G. Mills,et al. Sex-associated molecular differences for cancer immunotherapy , 2020, Nature Communications.
[34] C. Klein,et al. Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy , 2020, Science Translational Medicine.
[35] A. Kallies,et al. Precursor exhausted T cells: key to successful immunotherapy? , 2019, Nature Reviews Immunology.
[36] J. Stebbing,et al. A meta-analysis comparing responses of Asian versus non-Asian cancer patients to PD-1 and PD-L1 inhibitor-based therapy , 2020, Oncoimmunology.
[37] D. Schadendorf,et al. Tertiary lymphoid structures improve immunotherapy and survival in melanoma , 2020, Nature.
[38] Jung Kyoon Choi,et al. DNA methylation loss promotes immune evasion of tumours with high mutation and copy number load , 2019, Nature Communications.
[39] A. Abernethy,et al. Real‐world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer , 2019, Cancer.
[40] D. Baltimore,et al. Alternative mRNA splicing in cancer immunotherapy , 2019, Nature Reviews Immunology.
[41] G. Freeman,et al. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy. , 2019, Immunity.
[42] E. Wherry,et al. CD8 T Cell Exhaustion During Chronic Viral Infection and Cancer. , 2019, Annual review of immunology.
[43] Ash A. Alizadeh,et al. Determining cell-type abundance and expression from bulk tissues with digital cytometry , 2019, Nature Biotechnology.
[44] J. Lunceford,et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] Fan Zhang,et al. Fast, sensitive, and accurate integration of single cell data with Harmony , 2018, bioRxiv.
[46] K. Hiom,et al. DHX9 helicase promotes R-loop formation in cells with impaired RNA splicing , 2018, Nature Communications.
[47] Yassen Assenov,et al. Maftools: efficient and comprehensive analysis of somatic variants in cancer , 2018, Genome research.
[48] X. Liu,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[49] Marieke E. Ijsselsteijn,et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data , 2018, bioRxiv.
[50] Steven J. M. Jones,et al. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients , 2018, Cancer cell.
[51] P. Carmeliet,et al. Phenotype molding of stromal cells in the lung tumor microenvironment , 2018, Nature Medicine.
[52] R. V. van Lier,et al. Tissue-resident memory T cells at the center of immunity to solid tumors , 2018, Nature Immunology.
[53] A. Gupta,et al. Interferon Gamma Messenger RNA Signature in Tumor Biopsies Predicts Outcomes in Patients with Non–Small Cell Lung Carcinoma or Urothelial Cancer Treated with Durvalumab , 2018, Clinical Cancer Research.
[54] Matthew A. Wyczalkowski,et al. Systematic Analysis of Splice-Site-Creating Mutations in Cancer , 2018, Cell reports.
[55] R. Weinberg,et al. Understanding the tumor immune microenvironment (TIME) for effective therapy , 2018, Nature Medicine.
[56] R. Bourgon,et al. TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells , 2018, Nature.
[57] P. Hegde,et al. MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC , 2017 .
[58] J. Lunceford,et al. IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.
[59] A. Butte,et al. xCell: digitally portraying the tissue cellular heterogeneity landscape , 2017, bioRxiv.
[60] Jun S. Liu,et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy , 2016, Genome Biology.
[61] F. Hirsch,et al. PD‐L1 Expression in Lung Cancer , 2016, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[62] Robert Brown,et al. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer , 2015, Nucleic Acids Res..
[63] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[64] Yan Song,et al. Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells , 2015, Leukemia.
[65] R. Emerson,et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.
[66] Chonghui Cheng,et al. Cell type-restricted activity of hnRNPM promotes breast cancer metastasis via regulating alternative splicing , 2014, Genes & development.
[67] H. Choy,et al. hnRNP M facilitates exon 7 inclusion of SMN2 pre-mRNA in spinal muscular atrophy by targeting an enhancer on exon 7. , 2014, Biochimica et biophysica acta.
[68] G. Getz,et al. Inferring tumour purity and stromal and immune cell admixture from expression data , 2013, Nature Communications.
[69] Justin Guinney,et al. GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.
[70] D. Rotin,et al. LAPTM5 Protein Is a Positive Regulator of Proinflammatory Signaling Pathways in Macrophages* , 2012, The Journal of Biological Chemistry.
[71] Peter Langfelder,et al. Fast R Functions for Robust Correlations and Hierarchical Clustering. , 2012, Journal of statistical software.
[72] Trevor Hastie,et al. Regularization Paths for Generalized Linear Models via Coordinate Descent. , 2010, Journal of statistical software.
[73] S. Horvath,et al. WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.
[74] G. Eele. The Challenges , 2006 .
[75] P. Shannon,et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.
[76] Liquid Biopsies. Non-small-cell lung cancer , 2015, Nature Reviews Disease Primers.
[77] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.
[78] Andrew E. Jaffe,et al. Bioinformatics Applications Note Gene Expression the Sva Package for Removing Batch Effects and Other Unwanted Variation in High-throughput Experiments , 2022 .